DermTech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMTKQ research report →
About the company
DermTech, Inc. operates as a molecular diagnostics firm specializing in developing and commercializing innovative, non-invasive genomic tests designed to assist in the early detection and ongoing management of melanoma within the United States. Its flagship product, the DermTech Melanoma Test (DMT), offers a non-surgical method for improved melanoma detection, with further development underway for non-melanoma skin cancers.
- CEO
- Burkhard Jansen
- IPO
- 2017
- Employees
- 206
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $3.50K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.18
- Div Yield
- 0.00%
- Gross Margin
- 1.80%
- Op Margin
- -678.21%
- Net Margin
- -659.57%
- ROE
- -106.46%
- ROIC
- -92.98%
- Revenue
- $15.30M · 5.36%
- Net Income
- $-100,888,000 · 13.54%
- EPS
- $-3.09 · 20.36%
- Op Income
- $-103,739,000
- FCF YoY
- 20.99%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.87
- Avg Volume
- 7.26K
Get TickerSpark's AI analysis on DMTKQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DMTKQ coverage
Recent articles, reports, and earnings notes.
No research on DMTKQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMTKQ report →Similar companies
Peers in the same neighborhood.